Who are Tonix Pharmaceuticals Holding Corp.'s main suppliers?

Tonix Pharmaceuticals Holding Corp. (TNXP) key suppliers include: EVERANA. View the full supplier network at chainsifter.com/chain/TNXP.

Who are Tonix Pharmaceuticals Holding Corp.'s major customers?

Tonix Pharmaceuticals Holding Corp. (TNXP) key customers include: GROUP-PURCHASING-ORGANIZATION, CUSTOMERS, SPECIALTY-PHARMACIES, NATIONAL-PHARMACEUTICAL-WHOLESALERS, SPECIALTY-DISTRIBUTORS and 13 more. View the full customer network at chainsifter.com/chain/TNXP.

What sector is Tonix Pharmaceuticals Holding Corp. in?

Tonix Pharmaceuticals Holding Corp. (TNXP) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Tonix Pharmaceuticals Holding Corp. (TNXP) Supply Chain: 22 Verified Relationships

1Suppliers

18Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Tonix Pharmaceuticals Holding Corp. (TNXP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

23Total relationships

3Distinct source URLs

10High confidence

0.790Average confidence

2026-09-14Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Tonix Pharmaceuticals Holding Corp. Suppliers

Ticker	Name	Confidence	Evidence
EVERANA	EVERANA	90%	In 2024, Tonix engaged EVERSANA to support the launch strategy and commercial planning of TONMYA for the treatment of fibromyalgia.

Tonix Pharmaceuticals Holding Corp. Customers

Ticker	Name	Confidence	Evidence
GROUP-PURCHASING-ORGANIZATION	GROUP-PURCHASING-ORGANIZATION	92%	On May 6, 2026, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced it entered into an agreement with a group purchasing organization (“GPO”) that provides coverage for TONMYA ® .
CUSTOMERS	CUSTOMERS	90%	For the three months ended March 31, 2026, revenues from three customers accounted for 30 %, 28 % and 18 % of net product revenues, respectively.
SPECIALTY-PHARMACIES	SPECIALTY-PHARMACIES	90%	Tonix has contracted with its existing wholesalers and specialty pharmacies for the distribution of TONMYA.
NATIONAL-PHARMACEUTICAL-WHOLESALERS	NATIONAL-PHARMACEUTICAL-WHOLESALERS	85%	TONMYA is distributed in the United States through national pharmaceutical wholesalers and specialty distributors pursuant to customary commercial arrangements.
SPECIALTY-DISTRIBUTORS	SPECIALTY-DISTRIBUTORS	85%	TONMYA is distributed in the United States through national pharmaceutical wholesalers and specialty distributors pursuant to customary commercial arrangements.
AXSM	Axsome Therapeutics, Inc.	72%	arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketing approach focused on the top prescribing healthcare providers who treat patients…
AXSM	Axsome Therapeutics, Inc.	72%	Reciprocal relationship from AXSM graph: Reciprocal relationship from TNXP graph: arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketi…
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from AZN graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from AZN grap…
AZN	AstraZeneca PLC	72%	arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketing approach focused on the top prescribing healthcare providers who treat patients…
BNTX	BioNTech SE	72%	Reciprocal relationship from BNTX graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from TNXP graph: arket strategy. Our commercializati…
BNTX	BioNTech SE	72%	arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketing approach focused on the top prescribing healthcare providers who treat patients…
DFTX	Definium Therapeutics, Inc.	72%	Reciprocal relationship from DFTX graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from DFTX graph: Reciprocal relationship from TNXP graph: arket strategy. Our commercializati…
DFTX	Definium Therapeutics, Inc.	72%	arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketing approach focused on the top prescribing healthcare providers who treat patients…
DWTX	Dogwood Therapeutics, Inc.	72%	arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketing approach focused on the top prescribing healthcare providers who treat patients…
DWTX	Dogwood Therapeutics, Inc.	72%	Reciprocal relationship from DWTX graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from DWTX graph: Reciprocal relationship from TNXP graph: arket strategy. Our commercializati…
JNJ	Johnson & Johnson	72%	arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketing approach focused on the top prescribing healthcare providers who treat patients…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from TNXP graph: Reciprocal relationship from JNJ grap…
UPSHER-SMITH-LABORATORIES-LLC	UPSHER-SMITH-LABORATORIES-LLC	62%	expected to affect future collections experience. Any allowance would reduce the net receivables to the amount that is expected to be collected. The payment history of the Company’s customers will be…

Tonix Pharmaceuticals Holding Corp. Debt Obligations

Instrument	Description	Confidence	Evidence
TNXP-DEBT	Debt stack $7.5M	90%	Market cache reports total debt of $7.5M.
TNXP-DEBT-13046	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2013-12-31.
TNXP-DEBT-13045	Warrants outstanding: 4.25	90%	xbrl warrant detail from xbrl 2024-12-31.

Tonix Pharmaceuticals Holding Corp. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Tonix Pharmaceuticals Holding Corp..

Tonix Pharmaceuticals Holding Corp. Ownership

Holder	Name	Confidence	Evidence
TNXP-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 82 tracked holders.

Tonix Pharmaceuticals Holding Corp. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
ALC	Alcon Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
SNNUF	Smith & Nephew plc	100.00	2
AUTL	Autolus Therapeutics plc	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	2
CSTE	Caesarstone Ltd.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
AORT	Artivion, Inc.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
DEO	Diageo plc	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
CCCC	C4 Therapeutics, Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
BNRG	Brenmiller Energy Ltd	100.00	2
ATRA	Atara Biotherapeutics, Inc.	100.00	2

Tonix Pharmaceuticals Holding Corp. Supply Chain